On September 5 2023, ASCENDIS PHARMA A/S ($NASDAQ:ASND) released their financials for the quarter ending June 30 2023. The company reported total revenue of EUR 47.4 million, up from EUR 6.2 million in the same period for the prior year. On the other hand, net income was EUR -121.4 million in comparison to EUR -81.3 million in Q2 FY2022.
On Tuesday, ASCENDIS PHARMA A/S announced strong second quarter earnings for FY2023. The stock opened at $97.4 and closed at $99.7, representing an increase of 1.5% from its prior closing price of 98.3. The strong earnings are in part thanks to the company’s focus on innovation and its commitment to investing in its infrastructure and research and development divisions. In the second quarter, ASCENDIS PHARMA A/S invested more than $100 million in R&D projects, which has already started to show results by bringing new products to the market.
The company also expanded its international markets, increasing its presence in key markets like Europe and Asia. The company is expected to continue to invest in new projects while expanding its presence in international markets, which will drive revenue and profitability in the future. Investors seem to have taken notice of the company’s strong performance, as the stock price has risen steadily since the announcement of its second quarter earnings. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for ASND. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for ASND. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for ASND. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for ASND are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we’ve conducted an in-depth analysis of the financials of ASCENDIS PHARMA A/S to give investors an idea of the potential risks associated with investing in this company. Based on our Risk Rating, it is deemed to be a high risk investment. We’ve identified four risk warnings in the company’s income sheet, balance sheet, cashflow statement and financial journal. It’s important to note that the risks could change over time, so it’s important for investors to stay up to date with the company’s financials. To gain a better understanding of the situation, we suggest registering on goodwhale.com to explore our analysis further. More…
Risk Rating Analysis
Star Chart Analysis
Ascendis Pharma A/S, Hard to Treat Diseases Inc, Shanghai Bio-heart Biological Technology Co Ltd, and China Regenerative Medicine International Ltd are all companies that focus on developing treatments for hard-to-treat diseases. While each company has its own unique approach, they all share the common goal of helping patients with difficult-to-treat conditions.
– Hard to Treat Diseases Inc ($OTCPK:HTDS)
Shanghai Bio-heart Biological Technology Co Ltd is a Chinese company that focuses on the research and development of cardiovascular therapeutics. The company’s market cap as of 2022 is 11.97 billion, and its ROE is -18.92%. Shanghai Bio-heart Biological Technology Co Ltd’s products include treatments for heart failure, myocardial infarction, and arrhythmia.
– Shanghai Bio-heart Biological Technology Co Ltd ($SEHK:02185)
China Regenerative Medicine International Ltd. is a Hong Kong-based investment holding company principally engaged in the provision of medical services. The Company operates its business through three segments. The In-patient Services segment is engaged in the provision of medical services to in-patients. The Out-patient Services segment is engaged in the provision of medical services to out-patients. The Others segment is engaged in the provision of other services. The Company operates a hospital, which is located in Shenzhen, the People’s Republic of China (PRC).
Investors have been closely monitoring the performance of Ascendis Pharma A/S since the release of their second quarter FY2023 earnings. Total revenue was up significantly, increasing from EUR 6.2 million to EUR 47.4 million year-over-year. Unfortunately, net income was not as impressive, decreasing from EUR -81.3 million to EUR -121.4 million.
Although the revenue increase is encouraging, investors may be concerned about the company’s poor profitability. It is unclear whether or not this trend will continue, so investors should closely monitor the quarterly results of this company before making any investing decisions.